eTable 1. Studies currently recruiting in Germany.

MATRIX	Multicenter phase III trial on high-dose chemotherapy and autologous stem cell transplantation compared with conventional chemotherapy for consolidation in primary CNS lymphoma Age: 18–65 years (65–70 years only if ECOG status 0–1)
MARTA	Multicenter phase II study on age-adapted high-dose therapy followed by autologous stem cell transplantation in fit older patients with newly diagnosed primary CNS lymphoma Age: >70 years, ECOG status ≤ 2 (65–70 if patients are not eligible for MATRIX))
PQR309	Open, non-randomized phase II study to evaluate the efficacy and safety of pan-PI3K and mTOR PQR309 in patients with relapsed or refractory primary CNS lymphoma Age ≥18 years, Karnofsky index (KPS) ≥70%
NOA-13	Prospective observational study on chemotherapy in non-specifically pre-treated patients with primary CNS lymphoma (PCNSL)

ECOG, Eastern Cooperative Oncology Group status; CNS, central nervous system